secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-040641
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.
- Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.
- KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.
- Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.
- Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/0001104659-25-040641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-040641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer